Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “November 14, 2025”.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 68    

Filtered results: 68

Finerenone and quality of life assessed using the EuroQol 5-Dimension questionnaire level-sum-score in patients with heart failure and mildly reduced or preserved ejection fraction

Yang M., et al, JACC: Heart Failure. 2025

Yang M , 01 10 2025

Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF

Ferreira JP., et al, Eur J Heart Fail. 2025

Ferreira JP, 01 10 2025

Navigating heart failure: a plain-language summary to empower people with heart failure

Code J., et al, Heart Failure Reviews. 2025

Code J, 01 10 2025

The challenges of using electronic medical records (EMR) to facilitate guideline-directed medical therapy (GDMT) for patients with heart failure (HF) and chronic kidney disease (CKD)

Desai N., et al, Heart Failure Reviews. 2025

Desai NR, 01 10 2025

Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial

Ostromiski JW., et al, European Journal of Heart Failure. 2025

Ostrominski JW, 01 09 2025

Incident heart failure in adults with mild to moderate chronic kidney disease

Girouard MP., et al, JACC: Heart Failure. 2025

Girouard MP, 01 09 2025

Anthropometric measures, cardiovascular outcomes, and treatment effects of finerenone in cardiovascular-kidney-metabolic disease: pooled participant-level analysis of three global trials

Ostrominski JW., et al, JACC. 2025

Ostrominski JW, 01 08 2025

Blinded withdrawal of finerenone after long-term treatment in the FINEARTS-HF trial

Vaduganathan M et al., JACC. 2025.

Vaduganathan M, 01 08 2025

Efficacy and tolerability of finerenone according to the use and dosage of diuretics: A prespecified analysis of the FINEARTS-HF randomized clinical trial

Chimura M et al., JAMA Cardiol. 2025.

Chimura M, 01 08 2025

Hyperkalemia in heart failure with reduced ejection fraction: implications and management

Beavers CJ et al., Heart Failure Reviews. 2025

Beavers CJ, 01 08 2025